Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor

This publication has 46 references indexed in Scilit:

• Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years
  JAMA Dermatology, 2025
• Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis
  JAMA Dermatology, 2024
• Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
  Drug Safety, 2023
• Interleukin‐23 Regulates Inflammatory Osteoclastogenesis via Activation of CLEC5A(+) Osteoclast Precursors
  Arthritis & Rheumatology, 2023
• Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors
  Dermatology and Therapy, 2023
• Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
  BioDrugs, 2022
• Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
  Dermatology and Therapy, 2021
• Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
  JAMA, 2020
• Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis
  CPT: Pharmacometrics & Systems Pharmacology, 2017
• IL-23/IL-17 axis in spondyloarthritis-bench to bedside
  Clinical Rheumatology, 2016